{"id":678212,"date":"2023-11-24T13:54:01","date_gmt":"2023-11-24T13:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=678212"},"modified":"2023-11-24T13:54:01","modified_gmt":"2023-11-24T13:54:01","slug":"major-depressive-disorder-market-latest-study-by-delveinsight-forecasts-remarkable-growth-during-the-forecast-period-202332-abbvie-biolite-bristolmyers-squibb-gh-research-janssen-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-market-latest-study-by-delveinsight-forecasts-remarkable-growth-during-the-forecast-period-202332-abbvie-biolite-bristolmyers-squibb-gh-research-janssen-novartis_678212.html","title":{"rendered":"Major Depressive Disorder Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | AbbVie, BioLite, Bristol-Myers Squibb, GH Research, Janssen, Novartis"},"content":{"rendered":"
\n
\"Major<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Major Depressive Disorder Market size in the seven major markets was approximately USD 5,600 million in 2021, and it is expected to grow by 2032. As per DelveInsight, the Major Depressive Disorder Market is anticipated to evolve immensely in the coming years owing to the launch of new therapies in the market and the rise in the number of cases of Major Depressive Disorder in the 7MM.<\/div>\n

DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Major Depressive Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Major Depressive Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Major Depressive Disorder treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Major Depressive Disorder: An Overview<\/strong><\/p>\n

Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. It has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. Major depressive disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.<\/p>\n

It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, one of which must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with Major Depressive Disorder.<\/p>\n

The treatment strategies for depression consist of both pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy, and transcranial magnetic stimulation. In recent years, psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines increasingly recommend psychotherapy as a monotherapy or in combination with antidepressants.<\/p>\n

Major Depressive Disorder Market Key Facts<\/strong><\/p>\n